PDX models


New Strategic PDX line launched : Check our Match-R collection !

Special PDX models established from patients who proved demonstrated acquired resistance to last generation therapies ! (only newly approved or in clinical evaluation drugs). Drive your future research now by clicking below !

Patient-derived tumor xenograft panels enhance the power of preclinical assays by :


  • Faithfully reproducing the biological features of human cancers in term of histology, genomics and proteomics
  • Providing established concordance between patient and xenograft drug responses
  • Covering molecular diversity of clinical disease
  • Allowing identification of responsive cancer types
  • Allowing biomarker exploratory studies for subsequent patient stratification



PDX collection



Cancer Type Subtypes
Breast TNBC, HER2+, ER+, PR+
Prostate Primary hormone-dependent, Hormone-independent variant
Brain Glioblastoma
Kidney Renal Cell Carcinoma (RCC)
Skin Melanoma, Merkel cell carcinoma
Pediatric liver tumors Hepatoblastoma, Rhabdoid tumor

PDX database content





Molecular database


  • gene sequences (NGS Illumina HiSeq technology)
  • manually currated gene mutation data
  • gene expression profiles (U133plus Affy)
  • copy number variarion data (SNP6.0 Affy)
  • miRNA expression data (miRNA array)
  • protein expression (markers)



Drug Response data


  • PDX response to conventional treatments



Patient data (on a case-by-case basis)


  • histology
  • treatment before surgery
  • disease stage


Tumor surgical samples are obtained with patient’s consent, grafted subcutaneously into immunodeficient mice and maintained by serial transplantations.
Xenografts are considered established after 3 passages and frozen stocks are made at low passages.